Top

Published in:

01-04-2018 | Original Article

Serum adenosine deaminase activity is increased in systemic lupus erythematosus patients and correlated with disease activity

Authors: Zhao-wei Gao, Guan-hua Zhao, Zhe Zhang, Jing Huang, Zi-yue Li, Hui-zhong Zhang, Ke Dong

Published in: Immunologic Research | Issue 2/2018

Abstract

Adenosine deaminase (ADA) has been found to be involved in autoimmune disease progression. To assess the potential application of serum ADA activity in diagnosing systemic lupus erythematosus (SLE) and evaluating SLE disease activity, we investigated the serum ADA activity of 120 SLE patients and 120 healthy controls in the present study. The results showed that serum ADA activity in SLE patients was significantly increased (median (IQR) = 14 (11–19) U/L) compared with that in healthy controls (median (IQR) = 8 (7–10) U/L). Based on a receiver operating characteristic curve analysis, the optimal cut-off value for using serum ADA activity to diagnose SLE patients was 10.5 U/L (specificity, 84.2%; sensitivity, 78.3%). The diagnostic performance of serum ADA activity for SLE patients was better than that of other conventional haematology markers. Moreover, serum ADA activity displayed an increasing trend with increasing SLE disease activity. Spearman’s correlation analysis showed that serum ADA activity was positively correlated with SLE disease activity. These findings suggest that serum ADA activity could be a diagnostic marker for SLE; moreover, measuring serum ADA activity may be helpful for evaluating and monitoring the disease activity of SLE patients.

Available only for authorised users

Hasko G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 2004;25(1):33–9. https://doi.org/10.1016/j.it.2003.11.003.CrossRefPubMed

Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov. 2008;7(9):759–70. https://doi.org/10.1038/nrd2638.CrossRefPubMedPubMedCentral

Franco R, Valenzuela A, Lluis C, Blanco J. Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes. Immunol Rev. 1998;161(1):27–42. https://doi.org/10.1111/j.1600-065X.1998.tb01569.x.CrossRefPubMed

Whitmore KV, Gaspar HB. Adenosine deaminase deficiency—more than just an immunodeficiency. Front Immunol. 2016;7:314. https://doi.org/10.3389/fimmu.2016.00314.CrossRefPubMedPubMedCentral

Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312(7):729–38. https://doi.org/10.1001/jama.2014.9132.

Cicalese MP, Ferrua F, Castagnaro L, Pajno R, Barzaghi F, Giannelli S, et al. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. 2016;128(1):45–54. https://doi.org/10.1182/blood-2016-01-688226.

Ferrua F, Brigida I, Aiuti A. Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency. Blood. 2010;10(6):551–6. https://doi.org/10.1182/blood-2016-01-688226.

Sauer AV, Morbach H, Brigida I, Ng YS, Aiuti A, Meffre E. Defective B cell tolerance in adenosine deaminase deficiency is corrected by gene therapy. J Clin Investig. 2012a;122(6):2141–52. https://doi.org/10.1172/jci61788. CrossRefPubMedPubMedCentral

Sauer AV, Brigida I, Carriglio N, Hernandez RJ, Scaramuzza S, Clavenna D, et al. Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID. Blood. 2012b;119(6):1428–39. https://doi.org/10.1182/blood-2011-07-366781.CrossRefPubMedPubMedCentral

10.

Sauer AV, Brigida I, Carriglio N, Aiuti A. Autoimmune dysregulation and purine metabolism in adenosine deaminase deficiency. Front Immunol. 2012c;3:265. https://doi.org/10.3389/fimmu.2012.00265.CrossRefPubMedPubMedCentral

11.

Vinapamula KS, Pemmaraju SV, Bhattaram SK, Bitla AR, Manohar SM. Serum adenosine deaminase as inflammatory marker in rheumatoid arthritis. J Clin Diagn Res: JCDR. 2015;9(9):Bc08–10. https://doi.org/10.7860/jcdr/2015/14296.6483.PubMedPubMedCentral

12.

Xun C, Zhao Y, Hu ZJ. Potential role of adenosine deaminase in the diagnosis of adult-onset Still’s disease. Rheumatol Int. 2013;33(5):1255–8. https://doi.org/10.1007/s00296-012-2532-z.CrossRefPubMed

13.

Taysi S, Polat MF, Sari RA, Bakan E. Serum adenosine deaminase and cytidine deaminase activities in patients with systemic lupus erythematosus. Clin Chem Lab Med. 2002;40(5):493–5. https://doi.org/10.1515/cclm.2002.085. CrossRefPubMed

14.

Nalesnik M, Nikolic JM, Jandric S. Adenosine deaminase and C-reactive protein in diagnosing and monitoring of rheumatoid arthritis. Medicinski Glasnik: Off Publ Med Assoc Zenica-Doboj Canton, Bosnia and Herzegovina. 2011;8(1):163–8.

15.

Saghiri R, Ghashghai N, Movaseghi S, Poursharifi P, Jalilfar S, Bidhendi MA, et al. Serum adenosine deaminase activity in patients with systemic lupus erythematosus: a study based on ADA1 and ADA2 isoenzymes pattern. Rheumatol Int. 2012;32(6):1633–8. https://doi.org/10.1007/s00296-011-1836-8.CrossRefPubMed

16.

Hitoglou S, Hatzistilianou M, Gougoustamou D, Athanassiadou F, Kotsis A, Catriu D. Adenosine deaminase activity and its isoenzyme pattern in patients with juvenile rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol. 2001;20(6):411–6.CrossRefPubMed

17.

Demir G, Borman P, Ayhan F, Ozgun T, Kaygisiz F, Yilmez G. Serum adenosine deaminase level is high but not related with disease activity parameters in patients with rheumatoid arthritis. Open Rheumatol J. 2014;8(1):24–8. https://doi.org/10.2174/1874312901408010024.CrossRefPubMedPubMedCentral

18.

Zamani B, Jamali R, Jamali A. Serum adenosine deaminase may predict disease activity in rheumatoid arthritis. Rheumatol Int. 2012;32(7):1967–75. https://doi.org/10.1007/s00296-011-1912-0.CrossRefPubMed

19.

Wang D, Huang S, Yuan X, Liang J, Xu R, Yao G, et al. The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus. Cell Mol Immunol. 2015;14(5):423–31. https://doi.org/10.1038/cmi.2015.89.CrossRefPubMed

20.

Ohl K, Tenbrock K. Regulatory T cells in systemic lupus erythematosus. Eur J Immunol. 2015;45(2):344–55. https://doi.org/10.1002/eji.201344280.CrossRefPubMed

21.

Mak A, Kow NY. Imbalance between endothelial damage and repair: a gateway to cardiovascular disease in systemic lupus erythematosus. Biomed Res Int. 2014;2014:178721–11. https://doi.org/10.1155/2014/178721.CrossRefPubMedPubMedCentral

22.

van den Berg L, Nossent H, Rekvig O. Prior anti-dsDNA antibody status does not predict later disease manifestations in systemic lupus erythematosus. Clin Rheumatol. 2006;25(3):347–52. https://doi.org/10.1007/s10067-005-0047-7. CrossRefPubMed

23.

Chung L, Flyckt RL, Colon I, Shah AA, Druzin M, Chakravarty EF. Outcome of pregnancies complicated by systemic sclerosis and mixed connective tissue disease. Lupus. 2006;15(9):595–9. https://doi.org/10.1177/0961203306071915.CrossRefPubMed

24.

Forger F, Matthias T, Oppermann M, Becker H, Helmke K. Clinical significance of anti-dsDNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis. Lupus. 2004;13(1):36–44. https://doi.org/10.1191/0961203304lu485oa.CrossRefPubMed

25.

Jolly M, Smaron M, Olsen Utset T, Ellman M. Are isolated antinucleolar antibodies a marker of scleroderma? J Clin Rheumatol: Pract Rep Rheumatic Musculoskelet Dis. 2003;9(5):291–5. https://doi.org/10.1097/01.rhu.0000089790.80026.f4.CrossRef

26.

van Venrooij WJ, Charles P, Maini RN. The consensus workshops for the detection of autoantibodies to intracellular antigens in rheumatic diseases. J Immunol Methods. 1991;140(2):181–9. https://doi.org/10.1016/0022-1759(91)90369-Q.CrossRefPubMed

Title: Serum adenosine deaminase activity is increased in systemic lupus erythematosus patients and correlated with disease activity
Authors: Zhao-wei Gao
Guan-hua Zhao
Zhe Zhang
Jing Huang
Zi-yue Li
Hui-zhong Zhang
Ke Dong
Publication date: 01-04-2018
Publisher: Springer US
Published in: Immunologic Research / Issue 2/2018
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-018-8984-9

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Serum adenosine deaminase activity is increased in systemic lupus erythematosus patients and correlated with disease activity

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice

Impaired natural killer cell subset phenotypes in human obesity

Chronic graft-specific cell-mediated immune response toward candidate xenogeneic biomaterial

T cell receptor-β J usage, in combination with particular HLA class II alleles, correlates with better cancer survival rates

CD27+TIM-1+ memory B cells promoted the development of Foxp3+ Tregs and were associated with better survival in acute respiratory distress syndrome

The human breast cancer-associated protein, the prolactin-inducible protein (PIP), regulates intracellular signaling events and cytokine production by macrophages